m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00527)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ARRDC4
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 2 (YTHDF2) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF2 | ||
Cell Line | Human umbilical cord blood CD34+ cells | Homo sapiens |
Treatment: YTHDF2 knockdown UCB CD34+ cells
Control: Wild type UCB CD34+ cells
|
GSE107956 | |
Regulation |
|
logFC: -8.12E-01 p-value: 3.74E-05 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between ARRDC4 and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 1.87E+00 | GSE49339 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YTHDF2 dependent manner in colorectal cancer. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||
Methyltransferase-like 14 (METTL14) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14 | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Treatment: siMETTL14 MDA-MB-231 cells
Control: MDA-MB-231 cells
|
GSE81164 | |
Regulation |
|
logFC: -1.00E+00 p-value: 7.16E-13 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YHTDF2 dependent manner in colorectal cancer. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||
Colorectal cancer [ICD-11: 2B91]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YHTDF2 dependent manner in colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YTHDF2 dependent manner in colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||